A new study published in the Lancet evaluated the effects of continued tamoxifen therapy on breast cancerrecurrence and survival. A total of 12,894 women with early breast cancer who had completed 5 years of treatment with tamoxifen were randomly allocated to continue tamoxifen to 10 years or stop at 5 years. The study found that women with ER-positive breast cancer who continued tamoxifen for 10 years had significant reductions in the risk of breast cancer recurrence, breast cancer mortality, and overall mortality especially after year 10. How do you think this study will impact breast cancer treatment guidelines?
For more information about the study, pleasesee the abstract in the Lancet (scroll to the top of the page)
“Image courtesy of [scottchan]/ FreeDigitalPhotos.net”